Background
AMP-activated protein kinase (
AMPK) is a well-known cellular energy-balancing sensor [
1,
2], an important cell proliferation inhibitor [
3], and a potential target for cancer treatment [
4]. Pharmacological activation of
AMPK using AICAR or metformin can inhibit the growth or induce apoptosis of a wide spectrum of cancer cells, including cervical [
5] and ovarian [
6‐
8] cancers, through modulation of p53, p27, or p21 activities and cellular activities such as cell polarity and mitosis [
2,
3,
9]
AMPK is a heterotrimer composed of a catalytic subunit (α) and two regulatory subunits (β and γ) [
2]. Each subunit has different isoforms, namely, α1, α2, β1, β2, γ1, γ2, and γ3 encoded by distinct genes, which enable the yielding of 12 possible heterotrimeric combinations. The functional aspects of
AMPK have been extensively studied recently and reviewed in metabolic diseases and human cancers [
2,
3]. In contrast, the expression levels of the individual subunits of AMPK and their clinical significance in human cancers are rarely investigated. It would be intriguing to delineate the expression status of all
AMPK subunits in ovarian cancer and their potential correlations with clinical presentations.
Therefore, in the present study, quantitative PCR (Q-PCR) and immunohistochemical (IHC) staining were used to determine the expressions and cellular locations of six AMPK subunits (α1, α2, β1, β2, γ1, and γ2) in ovarian tissues. The expressions of AMPK subunits in ovarian cancer were then correlated with the clinical data.
Methods
Clinical samples
To recruit tissues for research study, patient’s consent was obtained before surgery at Queen Mary Hospital, Hong Kong. The use of the clinical specimens was approved by the local Institutional Review Board. Tumors containing more than 70% tumor cells were only used in the present study. A total of 76 tumor samples surgically resected from primary ovarian cancer patients and 53 normal ovary samples from benign diseases (including 5 borderline cases) were randomly selected for this study. The histological subtypes and disease stages of the tumors were classified according to International Federation of Gynecology and Obstetrics (FIGO) criteria. Clinical data of patients were retrieved from the records kept at the Department of Obstetrics & Gynecology, Queen Mary Hospital, Hong Kong.
RNA extraction and quantitative PCR analysis
Total RNA from the ovarian tissues was prepared using the TRIzol reagent (Invitrogen). Quality and quantity of RNA were determined by agarose electrophoresis and spectrophotometry, respectively. The cDNA was then prepared using the Taqman reverse transcription kit according to the manufacturer’s instructions (Applied Biosystems, Foster City, CA). The gene expression assay kits were also purchased from Applied Biosystems. The primers and probes used to detect and quantify the expressions of AMPK subunits were AMPK-α1 (Assay ID: Hs00178893_m1); AMPK-α2 (Hs00178903_m1); AMPK-β1 (Hs00272166_m1); AMPK-β2 (Hs00271294_m1); AMPK-γ1 (Hs00176952_m1); and AMPK-γ2 (Hs00211903_m1).
The real-time quantitative PCR (Q-PCR) was performed in an ABI 7500 system (Applied Biosystems). The relative expression level of each gene was normalized against the endogenous
β-actin (Product no: 4326315E) control. The
GAPDH (Assay ID: Hs99999905_m1) control was also used to further verify the relative expression level of each gene. The relative quantity of the RNA expression was calculated using the comparative CT method with the 7500 System SDS software [
10].
Immunohistochemical staining
Immunohistochemical (IHC) staining for the six AMPK subunits was performed separately on an ovarian cancer tissue array (OVC1021) (Pantomics Inc, San Francisco, CA). The tissue array contains 97 cancer cases and 5 normal/benign cases. The antibodies against the six
AMPK subunits were all purchased from Cell Signaling Technology, Inc., USA. They were anti-AMPK-α1 (Cat. no.: 2795); anti-AMPK-α2 (2757); anti-AMPK-β1 (4182); anti-AMPK-β2 (4148); anti-AMPK-γ1 (4187); and anti-AMPK-γ2 (2536). In addition, the anti-phospho-AMPK-α (2535) was also use to detect the phospho-AMPK-α. The details of the IHC staining procedures have been published elsewhere [
11,
12]. The percentages of positively stained cells in tumors and normal epithelia were assessed. The proportions of positive cells were ranged from 10 to 100%, while the intensity of staining was scored as 0 (negative), 1 (very weak), 2 (weak), 3 (moderate), 4 (intense), and 5 (very intense) in the most strongly stained tumor area. The immunoreactivity score for each case was taken as percentage of positive cells multiplied by the intensity of staining.
Confocal microscopy
The cellular locations of
AMPK-α2,
-β1 and
-γ2 were examined in the ovarian cancer cells, A2780CP and SKOV3. The pCMV6–AMPK-α2–GFP, pCMV6–AMPK-β1–GFP and pCMV6–AMPK-γ2–GFP tagged plasmids (OriGene Technologies) were used. The analytical procedure has already been reported in a previous study [
12]. The fluorescence signals were captured through confocal microscopy.
Statistical analysis
Statistical analysis was performed using Chi-squared test to evaluate the relationship between gene expression (low/high) and clinicopathological parameters, including age, grade, stage, histological subtype and recurrence. The nonparametric Mann–Whitney test was used to determine the significance on the difference in the distribution of gene expression in cancer, borderline and normal samples. Kaplan-Meier and the log rank test were used for survival analyses (both overall survival; from diagnosis to death of any cause and disease-free survival; from diagnosis to relapse). The SPSS 15.0 software was used to carry out the statistical analyses. All P values reported were two-sided and P < 0.05 was considered as statistically significant.
Discussion
In the present study, the detection of the over-expressions of AMPK subunits in ovarian carcinomas was described. The high expressions of the AMPK subunits have significant correlations with one or more clinicopathological parameters. Concerning AMPK-γ subunits, the antibodies from another source were also used. However, they were still not good enough to reveal the expression of AMPK-γ subunits at the protein level by IHC. From Western blotting analysis, AMPK -γ1 and -γ2 were detectable in a number of human ovarian surface epithelial cell lines and ovarian cancer cell lines (data not shown). Thus, we excluded the possibility of negative expression of AMPK -γ1 and -γ2. Nevertheless, based on the good correlation between Q-PCR and IHC results on AMPK-α and -β subunits, the expressions of the AMPK-γ subunits measured by Q-PCR may also reflect the actual protein levels of the AMPK-γ subunits in ovarian tissues. Certainly, further confirmation is needed when antibodies against AMPK-γ subunits with the quality for IHC analysis become available in the future.
AMPK is a heterotrimer containing the α, β, and γ subunits, all of which are essential for kinase activity [
2]. Thus, the expressions of the three different subunits should be regulated closely to keep their levels in balance for the formation of the
AMPK complex. However,
AMPK-α2,
-β1,
-β2,
-γ1, and
-γ2 were independently over-expressed in ovarian carcinomas.
AMPK subunits are encoded by distinct genes located at different chromosomal regions (Table
2). This may explain their independent over-expressions during ovarian carcinogenesis. Further, the association between the expressions of a particular
AMPK subunit with a particular histological subtype of ovarian carcinoma further demonstrated that
AMPK subunits can express independently to one another. Our data provide evidence on the complexity of genetic alterations during the development of cancer.
In a previous study,
AMPK-α1 was over-expressed in about 50% of cases of cervical cancer [
11] but without association with any clinical parameters. In contrast, although no statistically significant over-expression of
AMPK-α1 was found in ovarian cancers, the high expression of
AMPK-α1 was associated with the mucinous type of ovarian carcinoma (Additional file
2: Table S1). The expression of
AMPK-α1 was predominantly found in the nuclei of cervical cancer cells [
11]. In contrast, in the present study,
AMPK-α1 expression was mainly found in the cytoplasm of ovarian cancer cells. Based on the results of these two studies, the over-expressions of different
AMPK subunits in human cancers can be hypothesized to be tumor-type specific. Different cancers may have different expression statuses of various
AMPK subunits. Further investigation is needed to delineate the expression status of
AMPK subunits in various human cancers and the clinical implications of their expressions during cancer development.
Consistent with another report [
13], ovarian cancer patients with high expressions of
AMPK-α2 with better prognosis were also found in the present study. Tumors with low expressions of
AMPK-α2 may be more aggressive in nature. This observation leads to another important question on the potential functional roles of
AMPK subunits in ovarian cancer. In addition, the IHC results indicated that
AMPK-α2 and
-β1 were also specifically detected in the nucleus and cell membrane, respectively. The active form of
AMPK was only detected in the cytoplasm (Figure
3), so this result implied that
AMPK-α2 and
-β1 subunits may have distinct functions other than just being components of the heterotrimeric
AMPK complex.
In an earlier study [
14], under hypoxic condition,
AMPK-α2 expression was up-regulated and shuttled to the nucleus to promote cell survival by enhancing the hypoxia-induced
VEGF expression in human glioblastoma cells. The potential function of
AMPK-α subunits was further demonstrated. In a yeast two-hybrid experiment utilizing the HeLa cDNA library, the specific interaction between
AMPK-α and
p73α was shown. Both
AMPK-α1 and
-α2 can repress the tumor suppressor function of
p73α and enhance the growth of H1299 (non-small cell lung carcinoma cell line) and U2OS (human osteosarcoma cell line) cells without involving the activity of AMPK [
15]. In another study by Li et al. [
16], the forced expression of
AMPK-β1 inhibits the growth of H1299 and U2OS cells. This finding indicates that different
AMPK subunits have different functional roles in controlling cell growth. Knowledge on the functional roles of
AMPK subunits in human cancers is still limited. In addition to expression status, further investigation of the functions of
AMPK subunits is warranted. Functional studies may help in understanding the roles of these subunits in ovarian carcinogenesis.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
CL and VWSL carried out most of the experiments and did the preparation of the manuscript. PMC did the immunohistochemical staining. HYSN provided the clinical samples and data and patient’s consent for the study. DWC and HYSN helped to analyze all the data and critical comments on the manuscript. All authors read and approved the manuscript to be submitted for publication.